23andMe has introduced Discover23, a new research initiative designed to give biopharma partners access to its extensive genetic data to enhance drug development and clinical trial outcomes. The platform, which is powered by Lifebit’s Trusted Research Environment, allows researchers to securely analyze data derived from over 15 million participants and 172 million genetic variants. Through Discover23, collaborators can explore disease biology, identify novel drug targets, and improve precision medicine efforts. Importantly, the system ensures participant privacy by stripping personal identifiers from genetic data.

By including input from over 4.7 billion phenotypic data points, Discover23 supports efforts to accelerate the development of targeted treatments. Researchers can also access analyses of more than 1000 disease cohorts, making this platform particularly valuable for those seeking to enhance clinical trial success rates.

Image Credit: 23andMe